122 related articles for article (PubMed ID: 3500719)
1. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
Fonne-Pfister R; Bargetzi MJ; Meyer UA
Biochem Biophys Res Commun; 1987 Nov; 148(3):1144-50. PubMed ID: 3500719
[TBL] [Abstract][Full Text] [Related]
2. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
4. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Zanger UM; Vilbois F; Hardwick JP; Meyer UA
Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
[TBL] [Abstract][Full Text] [Related]
5. Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson's disease.
Shahi GS; Moochhala SM; Lee EJ; Das NP
Ann Acad Med Singap; 1989 Jan; 18(1):93-7. PubMed ID: 2785364
[TBL] [Abstract][Full Text] [Related]
6. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus).
Uehara S; Uno Y; Inoue T; Murayama N; Shimizu M; Sasaki E; Yamazaki H
Drug Metab Dispos; 2015 May; 43(5):735-42. PubMed ID: 25735838
[TBL] [Abstract][Full Text] [Related]
7. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Leemann T; Bonnabry P; Dayer P
Life Sci; 1994; 54(14):951-6. PubMed ID: 8139385
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P4502D and -2C enzymes catalyze the oxidative N-demethylation of the parkinsonism-inducing substance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat liver microsomes.
Narimatsu S; Tachibana M; Masubuchi Y; Suzuki T
Chem Res Toxicol; 1996; 9(1):93-8. PubMed ID: 8924622
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
13. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors.
Boobis AR; Seddon CE; Davies DS
Biochem Pharmacol; 1986 Sep; 35(17):2961-5. PubMed ID: 3741485
[TBL] [Abstract][Full Text] [Related]
14. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.
Larrey D; Distlerath LM; Dannan GA; Wilkinson GR; Guengerich FP
Biochemistry; 1984 Jun; 23(12):2787-95. PubMed ID: 6432035
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
Masimirembwa CM; Hasler JA; Johansson I
Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
[TBL] [Abstract][Full Text] [Related]
16. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
17. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
18. Depression of the hepatic cytochrome P-450 monooxygenase system by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Shahi GS; Moochhala SM; Das NP
Pharmacol Toxicol; 1989 Jan; 64(1):107-10. PubMed ID: 2787911
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
[TBL] [Abstract][Full Text] [Related]
20. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
Masubuchi Y; Iwasa T; Hosokawa S; Suzuki T; Horie T; Imaoka S; Funae Y; Narimatsu S
J Pharmacol Exp Ther; 1997 Sep; 282(3):1435-41. PubMed ID: 9316857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
